Aktiesnakken — Juli 2010
-
-
Overall sales (oncology and autoimmune diseases)
of MabThera/Rituxan (rituximab), for non-Hodgkin?s
lymphoma (NHL), chronic lymphocytic leukemia (CLL)
and rheumatoid arthritis (RA), rose 9% to 3.3 billion
Swiss francs. Sustained growth in the oncology seg -
segment
was driven by further expansion of market share
in all lines of CLL therapy and continued strong use
in the product?s core NHL indications. Sales growth in
the RA segment continued to be driven by increased
use in patients with an inadequate respo -
mornings
-
VWS ser ud til at starte i 290 pt
-
Ude igen...
-
Tror det "sure" marked skræmmer lidt..
-
hvad skyldes det "sure" marked i dag?
-
bernanke rystede træet igår
-
så det har ikke noget at gøre med Obama i går?
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind